|
PERSONALIZE: 
Overlook
at Great Notch 150 Clove Road Little Falls, New Jersey 07424 Telephone: (973) 890-8988 Fax: (973) 890-8866 
|
Main | Faculty | Learning Objectives
Agenda | CME/CE | Disclosure | Technical Requirements
Dear Colleague: New therapies are emerging that target angiogenesis, which is critical to solid tumor growth. Over one third of all cancers diagnosed in the United States are solid tumors and despite recent advances in cancer therapy and prevention, the incidence of solid tumors continues to rise. Two new therapies were approved in 2004 that target specific molecules involved in angiogenesis. These drugs, VEGF and EGFR inhibitors, when used in combination with chemotherapy, have demonstrated activity in a number of cancer types, including colorectal and renal carcinomas. The emergence of this new class of drugs offers healthcare practitioners and the managed care industry an opportunity to reduce the toll of cancer. This webcast on emerging concepts in angiogenesis presents highlights from the 2005 American Society of Clinical Oncology Annual Meeting. The expert faculty discusses the role of VEGF and EGFR inhibitors for patients with advanced renal cell cancer, advanced colorectal cancer, breast malignancies, and recurrent non-small cell lung cancer, as well as implications for the future of cancer therapy. 2005 Cancer Update: What's New in Angiogenesis? (Highlights from the American Society of Clinical Oncology Annual Meeting) addresses some of your most important concerns regarding emerging therapies that target angiogenesis. It is sure to be an informative and valuable webcast. Sincerely, ChairClaiborne E. Reeder, RPh, PhD Professor of Pharmacoeconomics College of Pharmacy University of South Carolina Columbia, South Carolina
Activity Agenda Pharmacoeconomics of Cancer Management and Role of Angiogenesis Inhibitors in the Managed Care Setting Advances in Managing Angiogenesis in Non-Small Cell Lung Cancer (NSCLC) Impact of Angiogenesis Inhibitors in the Treatment of Colorectal Cancer, Renal Cell Carcinoma, and Breast Cancer top Target Audience This activity is designed for medical directors and pharmacy directors in the managed care setting who care for patients with cancer. Activity Goal The goal of this professional education activity is to review treatment options for patients with solid tumors. At the completion of this activity, participants should be able to:
Statement of Accreditation Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Projects In Knowledge designates this educational activity for a maximum of 1 Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies. Successful completion for up to 1 hour of CME credit requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest. This activity has been approved by the American Association of Critical-Care Nurses (ACCN) for 1.0 contact hour. Provider #00012705. Statement of Accreditation: PHARMACISTS Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  This activity has been planned and implemented in accordance Contract for Mutual Responsibility in CME/CE Projects In Knowledge has developed the Contract for Mutual Responsibility in CME/CE to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.For more information on the Contract for Mutual Responsibility in CME/CE, please click here. The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Updated Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Cathy Eng, MD, has received grant/research support from Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, and Sanofi-Aventis; and is on the speakers bureau for Pfizer Inc. Roy S. Herbst, MD, PhD, has received grant/research support from, is a consultant for, and is on the advisory board for AstraZeneca and Genentech, Inc. Paulo M. Hoff, MD, has received grant/research support from Genentech, Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Sanofi-Aventis Inc. Claiborne E. Reeder, RPh, PhD, is on the speakers bureau for AstraZeneca and Pfizer Inc; is on advisory boards for Applied Health Outcomes and AstraZeneca; and is a stockholder with Amylin, GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc. Peer Reviewer has disclosed no significant relationships. Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process. There may be discussion of unlabeled/unapproved uses of drugs or devices in this activity. The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge. This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient. This independent CME/CE activity is supported by an educational grant from Genentech, Inc. top |
 Peer Review process directed by the University of Pennsylvania School of Medicine Office of CME. To find out more information click here.
Termination Date: Estimated time for completion of this webcast:  This independent CME/CE Target Audience This activity is designed for medical directors and pharmacy directors in the managed care setting who care for patients with cancer. Activity Goal The goal of this professional education activity is to review treatment options for patients with solid tumors. |
